Currently approved and clinical blood stem cell therapies rely on editing cells outside the body (ex-vivo). This involves extracting stem cells from the patient, editing them individually at specialized manufacturing facilities, administering high-dose chemotherapy to destroy existing bone marrow, and then transplanting the corrected cells back. The process is inherently unscalable, toxic, and lengthy, often taking six months to a year.
At Immitra Bio, we are developing a novel in-vivo gene editing platform that reduces treatment time from months to days, eliminates the need for chemotherapy, and is delivered as an off-the-shelf drug that all patients with the same condition can receive. Our therapy enables safe, fast, and truly scalable approach to gene correction.
News
Videos and Presentations
Immitra Bio's pitch video